Marksans Pharma Soars 8% on USFDA Approval for Cough Drug

Marksans Pharma Receives Key USFDA Approval

Marksans Pharma Ltd. saw its shares climb significantly after announcing it had received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP. The approval covers both 100 mg and 200 mg strengths of the medication. This development marks another step in the company's expansion into the U.S. pharmaceutical market.

The approved product is a generic version of Pfizer Inc.'s Tessalon Capsules. According to the company's regulatory filing, the drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD). Benzonatate is a non-narcotic antitussive, which functions by numbing stretch receptors in the respiratory system, thereby suppressing the cough reflex. It is prescribed for symptomatic relief of persistent coughs associated with conditions such as bronchitis, pneumonia, and other respiratory infections.

Positive Market Reaction

Investors responded positively to the news, driving the company's stock up by 7.92% to close at Rs 169.60 on April 1, 2026. During the trading session, the stock reached an intra-day high of Rs 169.65 on the BSE. The trading volume indicated strong buying interest following the announcement. By midday, the share price was trading 7.67% higher at Rs 169.20, outperforming the broader market, as the BSE Sensex was up 2.46% at the same time.

Strong Q3 Financial Performance

This regulatory success comes on the back of a solid financial quarter for the company. For the third quarter of fiscal year 2026 (Q3 FY26), Marksans Pharma reported a consolidated net profit of Rs 113.20 crore, an increase of 8.26% compared to the same period in the previous fiscal year. Revenue from operations also saw a healthy jump of 10.64%, reaching Rs 754.42 crore in Q3 FY26 from Rs 681.84 crore in Q3 FY25. This steady growth highlights the company's effective execution and market strategy.

Management Commentary

Mark Saldanha, the Managing Director of Marksans Pharma, commented on the company's recent performance. He stated, “We delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6 per cent year-on-year, supported by steady execution across key markets and improved seasonal demand.” Saldanha also noted that margins expanded sequentially, driven by softer raw material costs, favorable currency movements, and an improving product mix. He attributed the growth in Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) to operating leverage.

Company Profile and Regulatory Standing

Headquartered in Mumbai, Marksans Pharma is a global pharmaceutical company engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company operates manufacturing facilities in India, the USA, and the UK, which are approved by major regulatory agencies, including the USFDA, the UK's MHRA, and Australia's TGA. Its product portfolio covers major therapeutic areas such as cardiovascular, central nervous system, antidiabetic, pain management, and gastroenterology.

The recent approval for Benzonatate is part of a series of successful regulatory milestones for the company. This consistent track record of securing approvals for generic drugs strengthens its product pipeline and competitive position in key international markets, particularly the United States.

Analysis and Forward Outlook

The USFDA's approval for Benzonatate capsules is a significant positive for Marksans Pharma. It not only allows the company to enter the market for a widely used cough suppressant but also reinforces its reputation as a reliable manufacturer of generic drugs. The immediate and strong positive reaction in its stock price reflects investor confidence in the company's ability to capitalize on this opportunity. The consistent financial growth, coupled with a strong regulatory track record, positions Marksans Pharma for sustained momentum in the coming quarters as it continues to expand its product offerings in the lucrative U.S. market.